Abstract
This report presents the findings of a global survey on current therapeutic
approaches to the treatment of Neuropathic Pain (NP). These findings were made
following the participation of more than 330 physicians, who provided details
of their treatments and prescribing practices.
View Report Description With estimated prevalence levels of 3-10%, the
treatment of Neuropathic Pain (NP) remains an area of significant unmet need.
NP is highly individual in its presentation, level, underlying pathology and
response to therapy. For some patients, available therapies give satisfactory
pain control. For many others, treatments are poor or do not work at all.
Therapeutic options include more than ten drug classes, which are commonly
prescribed in combinations tailored to individual patient needs.
Interventional treatments, such as peripheral nerve block and transcutaneous
electrical nerve stimulation, are also used as physicians seek other
approaches to treating NP. This background, the individual nature of NP and
the drug (or drug combination) options used to treat patients, has created a
complex therapeutic picture.
In a therapeutic field where treatments are often unsatisfactory, physicians
seek to extent their understanding of NP in an effort to define needs and
limitations. Knowledge in these areas is also important to drug developers,
who seek a better understanding of patient needs and outcomes, as part of
their own efforts to develop more effective therapies. To meet interest in
these areas, Biopharm Reports has conducted an in-depth global survey on
current treatments and drug prescribing practices, relating to NP. This survey
involved the participation of more than 330 physicians and clinical centres in
56 countries.
Overview:
- Comprehensive details of current treatments for NP, provided by more than
330 clinics in 56 countries
- In-depth information relevant to markets and opportunities in the NP
field.
- 98% of participants are practicing physicians, working in specialised
areas of pain treatment. Of these, 78% described themselves as specialists in
pain treatment.
- Leading participant countries were USA, Canada, UK, Australia, Denmark,
France, Brazil, Germany, Netherlands and Belgium.
- 74% of the clinical centres participating in this study were hospital pain
departments, specialised pain practices or private pain clinics. Detailed
information on the use of specific drug classes including tricyclic
antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers,
opioids, NSAIDS, cannabinoids and Capsaicin.
- Physicians have provided detailed feedback on the underlying pathologies
associated with NP, seen in their patients.
- Comprehensive information on the most frequently prescribed drugs from
nine drugs classes, including drug combinations, for the treatment of NP.
Biopharm Reports believes this provides the most comprehensive and up-to-date
review and analysis in this area, currently available.
- A detailed analysis of interventional methods used for the treatment of NP
(e.g. peripheral nerve block, TENS).
- An assessment of average levels of pain relief achieved in the treatment
of NP, in relation to 12 underlying conditions.
- Informative views of participating physicians on current limitations,
challenges and issues relating to the treatment of NP.
|
Related Report
|
View Cart
